Showing 1-10 of 23 grants

Title Institution Researcher Program Duration Total Award Amount
Mechanisms of B Cell Polyreactivity in Autoimmunity: Toward Precision Immunotherapy Regents of the University of Colorado Elena Hsieh Cures 01-September-2025 to 31-August-2026 $149.965,60
Anti-Serpin B13 Hu-mAb Lead Candidate Developability Assessment Mosaic Biosciences, Inc. Malavi Madireddi Cures 01-June-2025 to 01-April-2026 $293.674,00
Validation of Enzyme-linked immunosorbent assay (ELISA) to detect insulin autoantibodies Regents of the University of Colorado Liping Yu Cures 01-June-2025 to 31-May-2027 $453.852,00
Electrochemiluminescence-based islet autoantibody assays detect the islet autoimmunity earlier and more disease specific than radio-binding assay in the longitudinally followed new-born cohort of TEDDY study Regents of the University of Colorado Xiaofan Jia Cures 01-June-2025 to 31-May-2027 $499.989,00
Autoimmunity Screening for Kids (ASK) Regents of the University of Colorado Marian Rewers Cures 01-November-2024 to 31-October-2027 $3.074.807,75
Improving the Uptake and Applicability of the Clinical and Economic Optimization Platform for Type 1 Diabetes Screening Regents of the University of Colorado R. Brett McQueen Cures 01-September-2024 to 31-August-2026 $451.890,07
Cognitive behavioral therapy to address anxiety in pre symptomatic type 1 diabetes Regents of the University of Colorado Holly O'Donnell Cures 01-July-2024 to 30-June-2027 $600.000,00
Advanced CGM analyses for longitudinal monitoring of early-stage Type 1 Diabetes Regents of the University of Colorado Andrea Steck Cures 01-October-2024 to 30-September-2027 $900.000,00
Targeting sub-micron ultrasound contrast agents to the immune-infiltrated islet microenvironment in Type1 diabetes Regents of the University of Colorado Richard Benninger Cures 01-July-2024 to 30-June-2027 $900.000,00
Testing the role of the PI3K-AKT-FOXO1-CXCR4 pathway in the bone marrow selection of anti-insulin B cells in T1D Regents of the University of Colorado Roberta Pelanda Cures 01-November-2023 to 31-October-2026 $826.284,00